Professor Heather Payne chairs a discussion with Professor Kurt Miller, Ms Netty Kinsella and Professor David Dearnaley around advancements in the diagnosis and treatment of patients with prostate cancer.
Discussions around diagnosis highlighted the results of the PROMIS trial; with multiparametric MRI allowing more men with clinically insignificant disease to avoid biopsy. Active surveillance was also discussed as an important tool for the treatment of men with early or low risk disease.
Conversations around diagnosis for advanced disease focused around PSMA scanning which is perceived by the experts to have provided significant advancements in terms of specificity and sensitivity of diagnosis.
The group also discuss data around treatment of oligometastatic disease and the potential use of biomarkers and next generation sequencing in precision medicine, as well as the use of chemotherapy and abiraterone in combination with ADT as a promising treatment for patients with castration sensitive disease.
Looking to the future of treatment of patients with prostate cancer, the experts discuss the treatment of locally advanced disease and the use of abiraterone and docetaxel in this patient group. The importance of further understanding optimal combinations of treatment modalities for individual patients is also highlighted.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).